托珠单抗和类固醇治疗新型冠状病毒肺炎炼狱综合征
The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids.
作者信息
Selvaraj Vijairam, Finn Arkadiy, Li Jennifer, Dapaah-Afriyie Kwame
机构信息
Internal Medicine, Miriam Hospital, Providence, USA.
Hospital Medicine, Miriam Hospital, Providence, USA.
出版信息
Cureus. 2022 Feb 25;14(2):e22614. doi: 10.7759/cureus.22614. eCollection 2022 Feb.
Hyperinflammation is a key component of severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. It is imperative to distinguish severe COVID-19 from hyperinflammatory syndromes such as multisystem inflammatory syndrome (MIS) and hemophagocytic lymphohistiocytosis. There is a subset of post-COVID-19 patients who present with some symptoms characteristic of MIS in adults (MIS-A) yet do not meet all the criteria for a diagnosis. We describe the unique case of a patient with this kind of presentation who clinically improved following tocilizumab and corticosteroid usage.
高炎症是重症2019冠状病毒病（COVID-19）的关键组成部分，且与不良预后相关。必须将重症COVID-19与多系统炎症综合征（MIS）和噬血细胞性淋巴组织细胞增生症等高炎症综合征区分开来。有一部分COVID-19后患者出现了成人MIS（MIS-A）的一些特征性症状，但未满足所有诊断标准。我们描述了一例具有此类表现的患者的独特病例，该患者在使用托珠单抗和皮质类固醇后临床症状有所改善。
Zotero 插件